Adjunct extended‐release valproate semisodium in late life schizophrenia

Sajatovic, Martha; Coconcea, Nicoleta; Ignacio, Rosalinda V.; Blow, Frederic C.; Hays, Robert W.; Cassidy, Kristin A.; Meyer, William J.

doi:10.1002/gps.1854

Cited by 15 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 38 articles reached the screening stage, of which 3 were excluded because of demographic research, 44 – 46 1 which was irrelevant to schizophrenia 47 and 1 which did not include a direct comparison of valproate augmentation therapy, 11 , 48 , because they were nonclinical trials such as case report/series, comments, or review articles, 22 , 36 , 49 – 57 1 because it used retrospective data, 58 4 because of a lack of detailed data on treatment effect, 12 , 35 , 59 , 60 and 6 because of a lack of a control group. 29 , 61 – 65 After the screening procedure, a total of 11 articles remained for the current meta-analysis (Table 1 ). 8 , 25 – 27 , 30 – 34 , 37 , 66 …”

Section: Resultsmentioning

confidence: 99%

Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The duration of adding divalproex sodium for schizophrenia treatment is also different. Some research has argued that treatment was only seen as significant from the beginning of the administration to the second, third, and fourth weeks, while there are also studies reporting the benefits until the 12th week with no significant change thereafter (23)(24)(25)(26)(27)(28). Other studies showed no significant improvement at the end of the study and more benefits were seen at the beginning of the addition of divalproex sodium especially for the improvement of positive symptoms when compared to those who were not treated with Divalproex sodium (29).…”

Section: Discussionmentioning

confidence: 99%

Open Trial of the Addition of Divalproex Sodium for Improving the Symptoms of Batak and Non-Batak Males with Schizophrenia in North Sumatra, Indonesia

Prasanty

Effendy²,

Amin³

et al. 2019

Iran J Psychiatry Behav Sci

View full text Add to dashboard Cite

Background: Ethnicity is one of many intrinsic factors influencing the drug response and its severity in patients with schizophrenia. In North Sumatera, Indonesia, information is very limited on the effect of divalproex sodium in Batak and non-Batak tribes.Objectives: The study aimed to investigate differences in positive and negative syndrome scale (PANSS) scores between Batak and non-Batak males with schizophrenia receiving risperidone treatment alone or in combination with divalproex sodium.Methods: This open trial experimental study was conducted on 60 Batak and non-Batak male subjects with schizophrenia. The doses of divalproex sodium and risperidone were 1500 mg and 6 mg, respectively. The sample was obtained from Prof. Dr. M. Ildrem Psychiatric Hospital, North Sumatra, Indonesia, in a span of six months from September 2017 to February 2018. The mini international statistical classification of diseases-10 (Mini ICD-10) structured interviews were used for diagnosis. Results: There were no differences between the Batak and Non-Batak groups in the PANSS positive subscale score (P = 0.766), PANSS negative subscale score (P = 0.789), and PANSS total score (P = 0.673) in six weeks of observation. Conclusions: There were no significant differences in the PANSS scores between males with schizophrenia from Batak and non-Batak tribes who received risperidone monotherapy or combined with divalproex sodium.

show abstract

“…Their outcomes showed psychosis scores calculated by positive and negative syndrome scale (PANSS), global functioning as tested by global assessment scale (GAS), and depression, as measured by geriatric depression scale (GDS), to be significantly reduced in the patients. Thus, they concluded that an extended-release of VPA in older schizophrenia patients appeared to be effective and well-tolerated [168].…”

Section: Vpa Treatment In Schizophrenia Human Studiesmentioning

confidence: 98%

Mood Stabilizers in Psychiatric Disorders and Mechanisms Learnt from In Vitro Model Systems

Nayak

Rosh

Kustanovich

et al. 2021

IJMS

View full text Add to dashboard Cite

Bipolar disorder (BD) and schizophrenia are psychiatric disorders that manifest unusual mental, behavioral, and emotional patterns leading to suffering and disability. These disorders span heterogeneous conditions with variable heredity and elusive pathophysiology. Mood stabilizers such as lithium and valproic acid (VPA) have been shown to be effective in BD and, to some extent in schizophrenia. This review highlights the efficacy of lithium and VPA treatment in several randomized, controlled human trials conducted in patients suffering from BD and schizophrenia. Furthermore, we also address the importance of using induced pluripotent stem cells (iPSCs) as a disease model for mirroring the disease’s phenotypes. In BD, iPSC-derived neurons enabled finding an endophenotype of hyperexcitability with increased hyperpolarizations. Some of the disease phenotypes were significantly alleviated by lithium treatment. VPA studies have also reported rescuing the Wnt/β-catenin pathway and reducing activity. Another significant contribution of iPSC models can be attributed to studying the molecular etiologies of schizophrenia such as abnormal differentiation of patient-derived neural stem cells, decreased neuronal connectivity and neurite number, impaired synaptic function, and altered gene expression patterns. Overall, despite significant advances using these novel models, much more work remains to fully understand the mechanisms by which these disorders affect the patients’ brains.

show abstract

Adjunct extended‐release valproate semisodium in late life schizophrenia

Abstract: While extended-release valproate semisodium appears efficacious and well tolerated in older adults with schizophrenia, data from larger, controlled trials is needed.

Cited by 15 publications

References 29 publications

Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia

Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia

Open Trial of the Addition of Divalproex Sodium for Improving the Symptoms of Batak and Non-Batak Males with Schizophrenia in North Sumatra, Indonesia

Mood Stabilizers in Psychiatric Disorders and Mechanisms Learnt from In Vitro Model Systems

Contact Info

Product

Resources

About